CTOs on the Move

Ovid Therapeutics

www.ovidrx.com

 
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ovidrx.com
  • 1460 Broadway
    New York, NY USA 10036
  • Phone: 646.661.7661

Executives

Name Title Contact Details
Stephanie Licata
VP, Program Leadership & Portfolio Management Profile

Funding

Ovid Therapeutics raised $75M on 08/11/2015
Ovid Therapeutics raised $25.86M on 01/23/2017
Ovid Therapeutics raised $25M on 02/26/2019
Ovid Therapeutics raised $20M on 02/26/2019

Similar Companies

VNA Care Network

Since 1891, VNA Care Network has helped people of all ages cope with illness and injury where they most want to be at home.

Flugen

FluGen is driving the development of a universal flu vaccine to advance human health.

BIOMET 3i

BIOMET 3i is a Palm Beach Gardens, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DayTwo

Covers a range of chronic conditions— impacting over 50% of employees Type 2 DiabetesPrediabetesClinical ObesityNAFLD

Biopro Implants

Biopro Implants is a Port Huron, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.